検索
Vyne Therapeutics Inc
VYNEウォッチリストに追加
28.560USD
0.0000.00%
終値 07-27 16:00（ET）15分遅れの株価
18.71M時価総額
損失額直近12ヶ月PER
詳細情報 Vyne Therapeutics Inc 企業名
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Vyne Therapeutics Incの企業情報
企業コードVYNE
会社名Vyne Therapeutics Inc
上場日Jan 25, 2018
最高経営責任者「CEO」Domzalski (David)
従業員数13
証券種類Ordinary Share
決算期末Jan 25
本社所在地685 Route 202/206 N., Suite 301
都市BRIDGEWATER
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号08807
電話番号18007757936
ウェブサイトhttps://vynetherapeutics.com/
企業コードVYNE
上場日Jan 25, 2018
最高経営責任者「CEO」Domzalski (David)
Vyne Therapeutics Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
97.44K
-3.55%
Dr. Iain Stuart, Ph.D.
Dr. Iain Stuart, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
60.49K
-3.92%
Ms. Mutya Fonte Harsch, J.D.
Ms. Mutya Fonte Harsch, J.D.
Chief Legal Officer, General Counsel, Secretary
Chief Legal Officer, General Counsel, Secretary
52.11K
-6.65%
Mr. Steven L. Basta
Mr. Steven L. Basta
Independent Director
Independent Director
7.45K
--
Ms. Elisabeth A. Sandoval Little
Ms. Elisabeth A. Sandoval Little
Independent Director
Independent Director
--
--
Mr. David Domzalski
Mr. David Domzalski
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Sharon Barbari
Ms. Sharon Barbari
Independent Director
Independent Director
--
--
Mr. Patrick G. Lepore
Mr. Patrick G. Lepore
Lead Independent Director
Lead Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
97.44K
-3.55%
Dr. Iain Stuart, Ph.D.
Dr. Iain Stuart, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
60.49K
-3.92%
Ms. Mutya Fonte Harsch, J.D.
Ms. Mutya Fonte Harsch, J.D.
Chief Legal Officer, General Counsel, Secretary
Chief Legal Officer, General Counsel, Secretary
52.11K
-6.65%
Mr. Steven L. Basta
Mr. Steven L. Basta
Independent Director
Independent Director
7.45K
--
Ms. Elisabeth A. Sandoval Little
Ms. Elisabeth A. Sandoval Little
Independent Director
Independent Director
--
--
Mr. David Domzalski
Mr. David Domzalski
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
よくある質問
Vyne Therapeutics Incの上位5名の株主は誰ですか？
Vyne Therapeutics Incの上位5名の株主は以下のとおりです。Mr. Tyler Zeronda
Vyne Therapeutics Inc（VYNE）の株式を保有している機関の数はいくつですか？
2026Q1時点で、Vyne Therapeutics Incの株式を保有している機関は92社あり、保有株式の総市場価値は約11.08Mで、全体の33.26%を占めています。2025Q4と比較して、機関の持ち株は-1672969.00増加しています。